(Q44254754)

1 December 2017

title

Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation (English)

1 reference

1 December 2017

1 reference

2

1 reference

1 December 2017

Jean Herman

1

1 reference

1 December 2017

Ingeborg van den Heuvel

3

1 reference

1 December 2017

Johan Van Cleemput

4

1 reference

1 December 2017

Veronique Winnepenninckx

5

1 reference

1 December 2017

Rita Van Damme-Lombaerts

6

1 reference

1 December 2017

publication date

1 December 2002

1 reference

The Journal of Heart and Lung Transplantation

1 December 2017

published in

1 reference

1 December 2017

volume

21

1 reference

1 December 2017

issue

12

1 reference

1 December 2017

page(s)

1304-1309

1 reference

The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Lymphoproliferative disorders after organ transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Diagnosis and treatment of transplant-related lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid o

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900439-4

7 January 2021

10.1016/S1053-2498(02)00439-4

Identifiers

DOI

1 reference

1 December 2017

1 reference